KRAS Mutation Subtypes and Their Association with Other Driver Mutations in Oncogenic Pathways.
KRAS
cBioPortal
domain
mutation
predictive response
prognostic response
signaling pathway
therapeutic strategy
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
received:
08
01
2024
revised:
28
04
2024
accepted:
11
05
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
26
7
2024
Statut:
epublish
Résumé
The KRAS mutation stands out as one of the most influential oncogenic mutations, which directly regulates the hallmark features of cancer and interacts with other cancer-causing driver mutations. However, there remains a lack of precise information on their cooccurrence with mutated variants of KRAS and any correlations between KRAS and other driver mutations. To enquire about this issue, we delved into cBioPortal, TCGA, UALCAN, and Uniport studies. We aimed to unravel the complexity of
Identifiants
pubmed: 39056802
pii: cells13141221
doi: 10.3390/cells13141221
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
KRAS protein, human
0
Class I Phosphatidylinositol 3-Kinases
EC 2.7.1.137
PIK3CA protein, human
EC 2.7.1.137
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM